Xenetic Biosciences
US-based Xenetic Biosciences advances XCART, a personalized CAR T platform targeting tumor neoantigens.
Founded
2011US-based Xenetic Biosciences advances XCART, a personalized CAR T platform targeting tumor neoantigens.
Xenetic Biosciences, founded in Lexington, United States, is a biopharmaceutical company dedicated to advancing innovative immune-oncology technologies. Their core mission is to develop proprietary technology platforms that target high-value cancer indications. The company’s flagship product, XCART, is a personalized CAR T platform engineered to target patient-specific tumor neoantigens. Additionally, Xenetic focuses on targeting Neutrophil Extracellular Traps (NETs), which are significant drivers of cancer progression and metastasis, and developing the DNase I oncology platform to enhance cancer therapies.
Notable affiliated individuals and investors include a range of experts in biotechnology and oncology, though specific names are not provided. Key achievements for Xenetic Biosciences include the development and progression of their XCART platform and their innovative approach to targeting NETs. The overall impact of Xenetic Biosciences lies in their potential to significantly improve personalized cancer treatments and address resistance issues in current therapies, positioning them as a promising player in the biopharmaceutical industry.
Companies similar to Xenetic Biosciences include Nerx Biosciences, Anixa Biosciences, OncXerna Therapeutics and Xcell Biosciences.
Xenetic Biosciences was founded in 2011.
Xenetic Biosciences' headquarters is located in Framingham, MA, US.
Xenetic Biosciences' most recent funding round was for $488.8k (USD) in October 2022.
As of Oct 12, 2022, Xenetic Biosciences has raised a total of $47M (USD).
Xenetic Biosciences has 4 employees as of Feb 5, 2024.
OncXerna Therapeutics
oncxerna.com
